{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T06:04:21Z","timestamp":1789365861879,"version":"build-2803163510"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Crescentic immunoglobulin A nephropathy (IgAN) with Oxford C2 lesions (\u226525% crescents) represents a severe disease phenotype. Individual complement markers show inconsistent prognostic value. We developed a composite Complement Activation Index (CAI) and tested its association with renal progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study enrolled 157 biopsy-confirmed patients with crescentic IgAN. The CAI was derived from four components: (i) urinary C3 &amp;gt; 2.8mg\/L, (ii) serum C3 &amp;lt; 0.80 g\/L, (iii) glomerular C3 immunofluorescence intensity \u2265 2+, and (iv) presence of glomerular C1q deposition. Each component contributed 1 point, categorizing patients into low- CAI and high- CAI groups. The association between CAI and the composite kidney disease progression event, defined as doubling of serum creatinine or end-stage renal disease, was assessed using Cox proportional hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A high CAI (43.9%, 69\/157) was associated with worse baseline renal function (eGFR 39 vs. 65 mL\/min\/1.73 m\u00b2, P&amp;lt;0.001), higher proteinuria (4.6 vs. 2.3\u00a0g, P&amp;lt;0.001), and more advanced tubulointerstitial injury. Over a median follow-up of 34.1 months, 44 patients (28.0%) reached the composite endpoint. High CAI independently predicted adverse outcomes (adjusted HR 2.58, 95% CI 1.15\u20135.80, P\u00a0=\u00a00.022), with each 1-point increase associated with an 87% higher risk (HR 1.87, 95% CI 1.10\u20133.20, P\u00a0=\u00a00.021). Adding CAI to the Oxford MEST model improved time-dependent AUC at 36 months (0.79 vs. 0.75, \u0394AUC 0.04, 95% CI -0.02 to 0.12).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Higher CAI was independently associated with renal progression in crescentic IgAN. As an exploratory composite index, CAI may complement existing pathological risk stratification, but its incremental clinical utility requires prospective validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1915157","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:39:51Z","timestamp":1789364391000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["High complement activation index predicts renal progression in crescentic IgA nephropathy"],"prefix":"10.3389","volume":"17","author":[{"given":"Jingjing","family":"Wang","sequence":"first","affiliation":[{"name":"National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Jiang","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhui","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Nephrology, 923rd Hospital of the Joint Logistics Support Force","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanmao","family":"Tu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju'an","family":"Wang","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Wang","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoshan","family":"Liang","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wang","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Zhang","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghua","family":"Huang","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2025.04.004","article-title":"KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV)","volume":"108","author":"Rovin","year":"2025","journal-title":"Kidney Int"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1159\/000528967","article-title":"IgA nephropathy with crescents: A single-center experience","volume":"53","author":"Ramani","year":"2022","journal-title":"Am J Nephrol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1681\/ASN.2016040433","article-title":"A multicenter study of the predictive value of crescents in IgA nephropathy","volume":"28","author":"Haas","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford classification of IgA nephropathy 2016: An update from the IgA nephropathy classification working group","volume":"91","author":"Trimarchi","year":"2017","journal-title":"Kidney Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2025.01.014","article-title":"Treatment of patients with IgA nephropathy: A call for a new paradigm","volume":"107","author":"Floege","year":"2025","journal-title":"Kidney Int"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.04.029","article-title":"IgA nephropathy: The lectin pathway and implications for targeted therapy","volume":"104","author":"Barratt","year":"2023","journal-title":"Kidney Int"},{"key":"B7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41581-024-00885-3","article-title":"The pathogenesis of IgA nephropathy and implications for treatment","volume":"21","author":"Cheung","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014101000","article-title":"Current understanding of the role of complement in IgA nephropathy","volume":"26","author":"Maillard","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.676919","article-title":"Complement activation is associated with crescents in IgA nephropathy","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2023.11.005","article-title":"Systematic review of the link between Oxford MEST-C classification and complement activation in IgA nephropathy","volume":"9","author":"\u015etefan","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2020.03.017","article-title":"Arteriolar C4d in IgA nephropathy: A cohort study","volume":"76","author":"Faria","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.02530317","article-title":"Mesangial C4d deposits in early IgA nephropathy","volume":"13","author":"Segarra","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2026.2682078","article-title":"Clinical significance of serum complement levels and C3\/C4 ratio in IgA nephropathy: Histopathological correlates and prognostic implications","volume":"48","author":"Ergun","year":"2026","journal-title":"Ren Fail"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf200","article-title":"In situ assessment of glomerular C3\/C5 convertases indicates ongoing complement activation in IgA nephropathy","volume":"41","author":"Obrecht","year":"2026","journal-title":"Nephrol Dial Transplant"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.05.015","article-title":"The role of complement in kidney disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"106","author":"Vivarelli","year":"2024","journal-title":"Kidney Int"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11133569","article-title":"Crescents and IgA nephropathy: A delicate marriage","volume":"11","author":"Trimarchi","year":"2022","journal-title":"J Clin Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000000000242","article-title":"Treatment of IgA nephropathy: A rapidly evolving field","volume":"35","author":"El Karoui","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1681\/asn.0000000796","article-title":"Predictive value of the Oxford classification for the effect of glucocorticoid therapy in IgA nephropathy","volume":"37","author":"Shi","year":"2027","journal-title":"J Am Soc Nephrol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14124204","article-title":"Advances in complement inhibitory strategies for the treatment of glomerular disease: A rapidly evolving field","volume":"14","author":"Conversano","year":"2025","journal-title":"J Clin Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with Iptacopan in IgA nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.105961","article-title":"Proteomic profiling of IgA nephropathy reveals distinct molecular prognostic subtypes","volume":"26","author":"Chen","year":"2023","journal-title":"iScience"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2010.110","article-title":"Podocyte number predicts progression of proteinuria in IgA nephropathy","volume":"23","author":"Xu","year":"2010","journal-title":"Mod Pathol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.02.1400","article-title":"Pilot study of sC5b-9 and Bb fragment plasma levels in crescentic immunoglobulin A nephropathy","volume":"9","author":"Guzzo","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1117995","article-title":"Urinary complement profile in IgA nephropathy and its correlation with the clinical and pathological characteristics","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1172\/jci188345","article-title":"Role of local complement activation in kidney fibrosis and repair","volume":"135","author":"Portilla","year":"2025","journal-title":"J Clin Invest"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae215","article-title":"Apical tubular complement activation and the loss of kidney function in proteinuric kidney diseases","volume":"17","author":"Alkaff","year":"2024","journal-title":"Clin Kidney J"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfag019","article-title":"Single-nephron eGFR and kidney function decline in IgA nephropathy","volume":"41","author":"Yang","year":"2026","journal-title":"Nephrol Dial Transplant"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf059","article-title":"Active glomerular inflammation versus chronicity and fibrosis: The role of targeted therapies in IgA nephropathy","volume":"40","author":"Radhakrishnan","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"B29","doi-asserted-by":"publisher","first-page":"898","DOI":"10.2215\/cjn.0000000000000471","article-title":"Development and external validation of a multidimensional deep learning model to dynamically predict kidney outcomes in IgA nephropathy","volume":"19","author":"Chen","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110354","article-title":"Roles of mesangial C3 and C1q deposition in the clinical manifestations and prognosis of IgAN","volume":"120","author":"Wang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000000674","article-title":"Relationship between serum C3\/C4 ratio and prognosis of immunoglobulin A nephropathy based on propensity score matching","volume":"133","author":"Zhang","year":"2020","journal-title":"Chin Med J (Engl)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1159\/000536114","article-title":"Combined effects of the serum IgA\/C3 ratio and glomerular C3 staining on the renal outcome in adult immunoglobulin A nephropathy","volume":"49","author":"Yang","year":"2024","journal-title":"Kidney Blood Press Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2026.106648","article-title":"Clinical value of kidney immunodeposits and urinary complement activation fragments in IgAN","volume":"11","author":"Royal","year":"2026","journal-title":"Kidney Int Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1915157\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:39:52Z","timestamp":1789364392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1915157\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":33,"alternative-id":["10.3389\/fimmu.2026.1915157"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1915157","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"article-number":"1915157"}}